What are the barriers to identifying and effectively treating patients at risk for thromboembolic disease? Join our panel of thrombosis experts, Drs Goldhaber, Hylek, McKean, and John Fanikos as they discuss strategies for reducing this deadly occurrence.
Join Drs Mahaffey, Hylek, Wallentin, and Weitz as they discuss the mechanisms by which various antithrombotic therapies target the coagulation cascade, the efficacy and safety of the currently available agents, and promising results from clinical trials of novel agents.
Join Drs Turpie, Kakkar, Eriksson and Lassen as they discuss the optimal targets for inhibition in the coagulation cascade and create a "wish list" of characteristics for the ideal oral anticoagulant: Is new clinical trial data realizing that wish?
On the RECORD: Join Drs Goldhaber, Turpie, Ansell and Kakkar as they discuss how new data from the RECORD 1, 2 and 3 studies on the use of oral factor Xa inhibitors will impact the prevention and treatment of venothromboembolism.
What are the barriers to identifying and effectively treating patients at risk for thromboembolic disease? Join our panel of thrombosis experts, Drs Goldhaber, Hylek, McKean, and John Fanikos as they discuss strategies for reducing this deadly occurrence.
Join Drs Harrington, Bode, Verheugt and Halperin as they discuss the spectrum of patients at risk for thrombotic events, strategies to prevent thrombosis on both sides of the circulation and recent clinical trial data which will impact patient care in the near future.
Join Drs Mahaffey, Hylek, Wallentin, and Weitz as they discuss the mechanisms by which various antithrombotic therapies target the coagulation cascade, the efficacy and safety of the currently available agents, and promising results from clinical trials of novel agents.